Plasmodium falciparum cytosolic ribosome

Protein synthesis in Plasmodium falciparum is carried out by specialized ribosomes and associated translational machinery, which are essential for parasite growth and survival during its erythrocytic stage. This process has significant differences compared to the human host, including structural adaptations in the ribosome to accommodate the unusual AT-rich and poly-lysine-rich mRNAs characteristic of the parasite[7]. Protein synthesis can be targeted therapeutically at multiple steps—by blocking ribosomal function, aminoacyl-tRNA synthetase activity, or elongation factors. Several drugs, including known translation inhibitors (cycloheximide, emetine, specific tRNA synthetase inhibitors, and the clinical-stage eEF2 inhibitor M5717), act by suppressing cytosolic protein translation within the parasite. Furthermore, certain antibiotics (doxycycline, clindamycin) inhibit protein synthesis within the apicoplast, a unique organelle in Plasmodium distinct from cytoplasmic translation. Resistance and selectivity highlight both a therapeutic opportunity and challenge for targeting this essential process in malaria parasites[2][4][6][7][8].

Other names

Plasmodium ribosomeP. falciparum ribosomePlasmodium translation machinerycytosolic ribosome of P. falciparum

Inhibition of ribosomal function (blocks mRNA translation); Inhibition of aminoacyl-tRNA synthetases (blocks charging of tRNA); Inhibition of translation elongation factors (e.g., eEF2 inhibition by M5717); Indirectly, apicoplast-targeting antibiotics inhibit plastid translation, affecting parasite viability.